Claims for Patent: 10,093,609
✉ Email this page to a colleague
Summary for Patent: 10,093,609
Title: | TAK1 kinase inhibitors, compositions, and uses related thereto |
Abstract: | The disclosure relates to TAK1 inhibitors, compositions, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula I, pharmaceutical compositions having a compound of formula I, and methods of treating or preventing cancer by administering an effective amount of a pharmaceutical composition having a compound of formula I to a subject in need thereof. |
Inventor(s): | Davies; Huw M. L. (Duluth, GA), Chennamadhavuni; Spandan (Natick, MA), Bakin; Andrei (Buffalo, NY) |
Assignee: | Emory University (Atlanta, GA) |
Application Number: | 15/694,982 |
Patent Claims: | 1. A method of treating cancer comprising administering a pharmaceutical composition comprising a compound of formula IC or salt thereof to a subject in need thereof,
wherein the cancer is selected from breast cancer, prostate cancer, lung cancer, colon cancer, liver cancer, ovarian cancer, cervical cancer, pancreatic cancer, renal cancer, thyroid cancer, melanoma, myeloma, lymphoma, leukemia, and neuroblastoma,
wherein formula IC is, ##STR00072## R1 is hydrogen, hydroxy, alkyl, alkoxy, carbocyclyl, aryl, or heterocyclyl, wherein R1 is optionally substituted with one or more, the same or different, R10; R2 is formyl, carboxy, or phosphonate, wherein R2 is
optionally substituted with one or more, the same or different, R10; R5 is hydrogen, alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl,
arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R5 is optionally substituted with one or more, the same or different, R10; R6 is hydrogen, alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio,
alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R6 is optionally substituted with one or more, the same or different, R10; R7 is hydrogen, alkyl, halogen, nitro, cyano, hydroxy, amino,
mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R.sup.7 is optionally substituted with one or more, the same or different,
R.sup.10; R8 is hydrogen, alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R8 is
optionally substituted with one or more, the same or different, R10; R9 is hydrogen, alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl,
arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R9 is optionally substituted with one or more, the same or different, R10; R10 is alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio,
alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R10 is optionally substituted with one or more, the same or different, R11; R11 is alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto,
formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R11 is optionally substituted with one or more, the same or different, R12; R12 is alkyl,
halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R12 is optionally substituted with one or
more, the same or different, R13; and R13 is halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino,
dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethyl sulfonyl,
methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl, or heterocyclyl.
2. The method of claim 1, wherein the compound is selected from: (2Z,4Z)-dimethyl 2-(3,4-dichlorophenyl)hexa-2,4-dienedioate, (2Z,4Z)-dimethyl 2-(4-bromophenyl)hexa-2,4-dienedioate, (2Z,4Z)-dimethyl 2-(4-iodophenyl)hexa-2,4-dienedioate, and (2Z,4Z)-dimethyl 2-(4-nitrophenyl)hexa-2,4-dienedioate. 3. The method of claim 1, wherein the subject is diagnosed with a tumor or malignant tumors derived from epithelial cells. 4. The method of claim 1, further comprising administering the compound of formula IC or salt thereof in combination with an additional active agents. 5. The method of claim 4, wherein the additional active agent is a chemotherapy agent. 6. The method of claim 5, wherein the chemotherapy agent is cis-platin or carboplatin. 7. The method of claim 5, wherein the chemotherapy agent is cyclophosphamide. 8. The method of claim 5, wherein the chemotherapy agent is doxorubicin. 9. The method of claim 5, wherein the chemotherapy agent is epirubicin. 10. The method of claim 5, wherein the chemotherapy agent is methotrexate. 11. The method of claim 5, wherein the chemotherapy agent is taxol or taxotere. 12. The method of claim 5, wherein the chemotherapy agent is 5-fluorouracil or tegafur. 13. The method of claim 5, wherein the chemotherapy agent is trastuzumab. 14. The method of claim 5, wherein the chemotherapy agent is gemcitabine. 15. The method of claim 5, wherein the chemotherapy agent is vinorelbine. 16. The method of claim 5, wherein the chemotherapy agent is tamoxifen. 17. The method of claim 5, wherein the chemotherapy agent is imatinib. |
Details for Patent 10,093,609
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2031-07-19 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2031-07-19 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2031-07-19 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.